Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Caspofungin Acetate

FDA-approved product (powder, intravenous), marketed as Cancidas, Caspofungin Acetate.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
4 of 4

Chemical structure

Chemical structure of Caspofungin Acetate
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Aspergillosis
  • Candidemia
  • Candidiasis
  • Fungal infectious disease

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Other antimycotics for systemic use
Anti-infective classification
Classified as another kind of anti-infective (for example an antifungal, antiviral or antiparasitic medicine).WHO ATC J02AX04

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against E. coli, MRSA, K. pneumoniae and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA65.5% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli53.7% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae57.5% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis61.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Caspofungin Acetate in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Caspofungin Acetate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Voriconazole and Caspofungin Acetate in Treating Invasive Fungal Infections in Patients With Weakened Immune Systems

    NCT00238355 · start 2003-08

    Registered record
    Registry ID
    NCT00238355
    Conditions
    Infection; Unspecified Adult Solid Tumor, Protocol Specific
    Interventions
    caspofungin acetate; voriconazole
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2003-08
    Completion
    2008-06
    Enrolment
    13

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionInfection; Unspecified Adult Solid Tumor, Protocol Specific
    Interventioncaspofungin acetate; voriconazole
    PhasePhase 2
    Registry statusTerminated

  • MK0991 in Combination With Standard Antifungal Agent(s) for the Treatment of Salvage Invasive Aspergillosis (0991-037)

    NCT00076869 · start 2003-01

    Registered record
    Registry ID
    NCT00076869
    Conditions
    Aspergillosis
    Interventions
    MK0991, caspofungin acetate; Comparator: amphotericin B; Comparator: lipid formulation of amphotericin B and/or azole
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2003-01
    Completion
    2005-08
    Enrolment
    55

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAspergillosis
    InterventionMK0991, caspofungin acetate; Comparator: amphotericin B; Comparator: lipid formulation of amphotericin B and/or azole
    PhasePhase 2
    Registry statusCompleted

  • Caspofungin Acetate in Treating Children With Fever and Neutropenia

    NCT00020527 · start 2001-03

    Registered record
    Registry ID
    NCT00020527
    Conditions
    Fever, Sweats, and Hot Flashes; Infection; Kidney Cancer; Leukemia; Lymphoma; Neuroblastoma; Neutropenia; Sarcoma
    Interventions
    caspofungin acetate
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2001-03
    Completion
    2003-06
    Enrolment
    Not recorded

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionFever, Sweats, and Hot Flashes; Infection; Kidney Cancer; Leukemia +4 more
    Interventioncaspofungin acetate
    PhaseNot applicable
    Registry statusCompleted

  • Caspofungin Acetate Compared With Amphotericin B Liposomal in Treating Patients With Persistent Fever and Neutropenia Following Cancer Treatment

    NCT00008359 · start 2000-08

    Registered record
    Registry ID
    NCT00008359
    Conditions
    Cancer
    Interventions
    caspofungin acetate; liposomal amphotericin B
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2000-08
    Completion
    Not recorded
    Enrolment
    Not recorded

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCancer
    Interventioncaspofungin acetate; liposomal amphotericin B
    PhasePhase 3
    Registry statusCompleted

  • Safety and Effectiveness of Giving L-743,872 to Patients With Thrush That Has Not Been Cured With Fluconazole

    NCT00005920

    Registered record
    Registry ID
    NCT00005920
    Conditions
    Candidiasis, Oral; HIV Infections
    Interventions
    L-743,872
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    Not recorded
    Completion
    Not recorded
    Enrolment
    70

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCandidiasis, Oral; HIV Infections
    InterventionL-743,872
    PhasePhase 2
    Registry statusTerminated